Prosecution Insights
Last updated: November 04, 2026

Inhouse Patent Counsel, LLC

Technology area: Biotechnology & Pharmaceuticals

5 pending office actions • 5 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready

Analysis

InHouse Patent Counsel, LLC has 5 pending office actions in Biotechnology & Pharmaceuticals and 255 career applications. The current docket is small, while the application base supplies context for interpreting the reported outcomes.

The resolved allowance rate is 86.62%, and the average is 4.01 office actions per allowance. The rate indicates favorable allowance results in the resolved record, while the action average indicates that allowance commonly follows extended examination activity. Practitioners should account for the apparent outcome strength alongside the higher response burden reflected in the action metric.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=255 apps, methodology: how we score firms)

86.6%
Allowance Rate
n=255
+0.94σ
Allowance Rate (norm)
n=255
4.0
OAs to Allowance
n=136
-0.14σ
OAs to Allow (norm)
n=136
988 days
Time to Allowance
n=136
+19.6pp
Interview Lift
n=255
23.6%
RCE Rate
n=255
0.0%
Appeal Rate
n=255

Rejection Performance (% of received rejections ultimately overcome)

93.8%
§101 Overcome
n=32
87.0%
§102 Overcome
n=69
89.6%
§103 Overcome
n=77
85.4%
§112 Overcome
n=110

Specialization & Scale

C12N, A61K, C12Y
Top CPC Subclasses
45%
Top-3 CPC Share
n=255
1
Practitioners
n=255
255.0
Apps / Practitioner
n=255

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
0
Medium (0%)
4
Easy (80%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only4 (80%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
STEADMAN, DAVID J 1 57.7% +30.0%
RAMIREZ, DELIA M 1 65.1% +56.3%
SAEED, KAMAL A 1 83.9% +9.8%
SAIDHA, TEKCHAND 1 82.9% +14.1%
FLINDERS, JEREMY C 1 63.4% +17.1%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18705344 MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE SAEED, KAMAL A —
18477601 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS SAIDHA, TEKCHAND —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18173551 BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS FLINDERS, JEREMY C 16d overdue

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18173551 BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS FLINDERS, JEREMY C 16d overdue
18950126 TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES STEADMAN, DAVID J —
18726717 HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING RAMIREZ, DELIA M —
18477601 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS SAIDHA, TEKCHAND —

Client Portfolio (5 clients)

Top Art Units

Art UnitApps
16522
16561
16261
16841

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18950126 TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES BRANDEIS UNIVERSITY STEADMAN, DAVID J 1656 §112 Non-Final OA — Pending Nov 17, 2024
18726717 HEMOSTATIC COMPOSITION CONTAINING RECOMBINANT HUMAN CLOTTING FACTORS, AND METHOD OF PRODUCING Regents Of The University Of Minnesota RAMIREZ, DELIA M 1652 §112 Non-Final OA — Pending Jul 03, 2024
18705344 MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE Zywie, LLC SAEED, KAMAL A 1626 §112 Final Rejection — Pending Apr 26, 2024
18477601 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS Global Bioenergies SAIDHA, TEKCHAND 1652 §112 Non-Final OA — Pending Sep 29, 2023
18173551 BIOMARKERS OF IMMUNE DYSFUNCTION IN RESPONSE TO CHRONIC STRESS, METHODS OF USE AND DIAGNOSTIC KITS The United States Government (Department of the Army) FLINDERS, JEREMY C 1684 §102§112Other Non-Final OA 16d overdue Pending Feb 23, 2023

Managing Inhouse Patent Counsel, LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Inhouse Patent Counsel, LLC's patent allowance rate?

86.6% of resolved applications prosecuted by Inhouse Patent Counsel, LLC were allowed, across 255 applications in USPTO records.

How many office actions does Inhouse Patent Counsel, LLC average before allowance?

4.01 office actions per allowed application on average.

How many pending office actions does Inhouse Patent Counsel, LLC have?

5 pending office actions as of November 2026, for 5 clients, before 5 examiners in 4 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month